MedTrace Logo

Comparison of Intratechal Levobupivacaine and Adding With Sufetanil and Fentanyl in Ceserean Section

NCT02430090 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2021-11-19

Study results available
· View outcomes & findings →

Summary

45 pregnant women undergoing cesarean section were enrolled in the study in november 2006 to march 2007. 2 ml of 0.5% levobupivacaine was added to 1 ml of saline in group I, 1 ml of 15 µcg of fentanyl in group II and 1 ml of 1,5 µcg sufentanil in group III by intratechal administration. Hemodynamic parameters, characteristics of sensory and motor blockade, peri-operative and postoperative visual analogue scale (VAS) pain scores, the time to the first analgesic requirement and adverse effects were recorded.

Conditions

  • Anesthesia

Interventions

DRUG

Levobupivacaine

this used in intratechal area and for spinal anesthesia in ceserean section

DRUG

Fentanyl

this used in intratechal area and for spinal anesthesia in ceserean section

DRUG

Sufentanil

this used in intratechal area and for spinal anesthesia in ceserean section

DRUG

Levobupivacaine

this used in intratechal area and for spinal anesthesia in ceserean section

DRUG

Levobupivacaine

this used in intratechal area and for spinal anesthesia in ceserean section

Sponsors & Collaborators

  • Ankara City Hospital Bilkent

    lead OTHER

Principal Investigators

  • Müge Çakırca · Ankara Numune Training and Research hospital, Anesthesiology and Reanimation Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2007-03-31
Completion
2007-03-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02430090 on ClinicalTrials.gov